PT  - JOURNAL ARTICLE
AU  - Mbona, Sizwe Vincent
AU  - Mwambi, Henry
AU  - Chifurira, Retius
TI  - Identifying risk factors associated with death among patients with MDR-TB in KwaZulu-Natal, South Africa: an illustration using Weibull parametric model
AID  - 10.1101/2022.03.01.22271638
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.01.22271638
4099  - http://medrxiv.org/content/early/2022/03/04/2022.03.01.22271638.short
4100  - http://medrxiv.org/content/early/2022/03/04/2022.03.01.22271638.full
AB  - Background This study aim was to identify the risk factors associated with multidrug-resistant tuberculosis (MDR-TB) disease. The Weibull model has shown to perform better than the Cox proportional models with respect to the accuracy and efficient of the estimates. Therefore, a Weibull parametric model was employed to identify predictors of death in patients with MDR-TB and the efficiency of the models using current dataset.Methods Patients diagnosed with MDR-TB were studied in four decentralised sites located in rural areas and one centralised hospital in KwaZulu-Natal, South Africa from July 2008 to July 2012. Patients were followed from the date of MDR-TB diagnosis until death or the last follow-up date.Results A total of 1 542 patients were included in the analyses: 812 and 730 from the centralised hospital and decentralised sites, respectively. Of the 1 542 enrolled, 15.9% patients died. We found that the hazard of death was significantly higher among patients treated in decentralised sites (aHR) = 1.84, 95% CI = 1.38 – 2.75; SE = 0.81 than that of those who were treated in the centralised hospital. However, the results from the Cox PH model showed an insignificant hazard of death between the decentralised sites and the centralised hospital (aHR = 1.46, 95% CI = 0.69 – 2.36; SE = 0.92). Patients who are between 31 – 40 years of age had increased hazard of death compared to those between 18 – 30 years (aHR = 1.52, 95% CI = 1.04 - 2.23). The hazard of death in female patients was 24% higher compared to male patients (aHR = 1.24, 95% CI = 0.93 - 1.63). Furthermore, patients with previous MDR-TB episodes had an increased hazard of death (aHR = 1.79, 95% CI = 0.23 – 0.62) compared to those with no previous MDR-TB episodes. The hazard of death in HIV negative patients was low compared to those who were HIV positive (aHR = 0.95, 95% CI = 0.57 – 0.77).Conclusion More health facilities are needed especially in decentralised places and that can help the 2030 World Health Organisation strategy to reduce or end TB infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (Ref: BF052/09), and by the KwaZulu-Natal Department of Health. Only secondary data, the data routinely collected by health workers for clinical care was used in this study. To protect patient confidentiality and anonymity the data bases were de-identified and access strictly limited. Informed consent was waived by the ethics committee, since all patient data used were previously collected during the course of routine medical care and did not pose any additional risks to the patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.aHRAdjusted hazard ratioCIconfidence intervalS.Estandard errorSDStandard deviationHIVHuman immunodeficiency virusTBTuberculosisDRDrug-resistantMDR-TBMultidrug-resistant tuberculosis